Using gamma delta T cells to treat melanoma
Gamma delta T cell based melanoma therapies
This study is looking at new ways to treat melanoma using special immune cells called gamma delta T cells, and it involves testing these treatments in mice that are designed to act like humans, all to help boost the body's fight against tumors and improve how well treatments work for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10988313 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies for melanoma by utilizing gamma delta T cells, a unique type of immune cell. The approach involves creating humanized mouse models that closely mimic human immune responses to test the effectiveness of these therapies. By using patient-derived melanoma samples, the researchers aim to enhance the immune response against tumors and improve treatment outcomes. The study will also explore how these therapies affect the tumor microenvironment and the overall immune response.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with melanoma who may benefit from advanced immunotherapy treatments.
Not a fit: Patients with non-melanoma skin cancers or those who do not have access to the specific humanized mouse models may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized immunotherapy options for melanoma patients.
How similar studies have performed: Previous research has shown promising results with similar immunotherapy approaches, indicating potential for success in this novel application.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Xu, Xiaowei — University of Pennsylvania
- Study coordinator: Xu, Xiaowei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.